Home › Compare › BCNAF vs ABBV
BCNAF yields 4.96% · ABBV yields 3.06%● Live data
📍 BCNAF pulled ahead of the other in Year 5
Combined, BCNAF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BCNAF + ABBV for your $10,000?
Barco NV, together with its subsidiaries, develops visualization solutions for the entertainment, enterprise, and healthcare markets worldwide. The company operates through three divisions: Entertainment, Enterprise, and Healthcare. It offers cinema, installation, postproduction, rental, simulation, and virtual reality projectors; presentation switchers and screen management systems, scalers, cards, and controllers; LED image processing and indoor LED displays; and laser, LCD, LED rear-projection, and LED video walls, as well as video wall controllers and upgrade kits. The company also provides wireless conferencing and presentation systems. In addition, it offers 3D sound products; options and accessories, such as boards/cards, lamps, lenses, mechanics, sensors, and others; cinema software and control room collaboration systems; visual display systems comprising canvas, caves, power walls, reconfigurable displays, and transportable caves; and a portfolio of support, maintenance, training, and professional services. Further, the company provides critical decision-making solutions, such as breakout and control rooms, field workers, and operators; networked solutions for education, meetings, trainings, and operating rooms; operational collaboration systems; and AV streaming for encoders and decoders, and software clients. Additionally, it offers software products for clinical collaboration; and medical display systems, as well as solutions for operating rooms. Barco NV was founded in 1934 and is headquartered in Kortrijk, Belgium.
Full BCNAF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.